Study title: A randomized, multicenter, double-blind trial of Sandostatin LAR Depot (40 mg) versus saline-control in the treatment of pediatric hypothalamic obesity
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Nutritional and Metabolic Diseases [C18] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: OCTREOTIDE | |||||
| ATC code: H01CB02 | |||||
| Document link: Novartis Octreotide_Sandostatin LAR Study B2403E1_31Aug2011.xls | |||||
| Document date: 2011-09-16 | |||||
| Study number: SMS995B2403E1 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |